Pro-Dex (PDEX) Projected to Release Quarterly Earnings on Thursday

Pro-Dex (NASDAQ:PDEX) will likely be posting its Q1 2027 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $0.67 per share and revenue of $20.40 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2027 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 3:00 PM ET.

Pro-Dex (NASDAQ:PDEX) last released its quarterly earnings results on Thursday, September 3rd. The medical instruments supplier reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.20. The firm had revenue of $20.41 million during the quarter, compared to analyst estimates of $19.20 million. On average, analysts expect Pro-Dex to post $3.09 EPS for the current fiscal year and $3.36 EPS for the next fiscal year.

Pro-Dex Trading Up 2.7%

Shares of PDEX stock opened at $62.27 on Wednesday. The firm’s fifty day moving average price is $65.11 and its two-hundred day moving average price is $56.19. Pro-Dex has a 1 year low of $28.50 and a 1 year high of $77.00.

Insider Buying and Selling

In other news, CFO Alisha Charlton sold 2,300 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $61.30, for a total transaction of $140,990.00. Following the completion of the transaction, the chief financial officer directly owned 21,870 shares in the company, valued at $1,340,631. This trade represents a 9.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kirk Richard Lee Van, Jr. sold 19,235 shares of Pro-Dex stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $60.58, for a total transaction of $1,165,256.30. Following the transaction, the chief executive officer directly owned 79,993 shares of the company’s stock, valued at $4,845,975.94. This represents a 19.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 22,300 shares of company stock valued at $1,351,657. 48.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have weighed in on PDEX shares. Weiss Ratings cut shares of Pro-Dex from a “buy (b)” rating to a “hold (c+)” rating in a report on Friday. Zacks Research upgraded shares of Pro-Dex from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 15th. Finally, Ascendiant Capital Markets boosted their price objective on Pro-Dex from $70.00 to $74.00 and gave the stock a “buy” rating in a report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $74.00.

Pro-Dex Company Profile

Pro-Dex, Inc (NASDAQ:PDEX) designs, develops and manufactures powered surgical instruments and related products for the medical device industry. The company primarily serves original equipment manufacturers that incorporate Pro-Dex instruments into surgical systems sold under their own brands.

Its products include battery-powered and pneumatic handpieces, rotary instruments, micro-drills, saws, controllers and other specialized equipment used in orthopedic, dental, ophthalmic and other surgical applications.